RxDoctor Payments Data

Eddie Waldheim, MD

Family Medicine · Maitland, FLNPI 1881797082

Payments from drug & device makers

$470in general payments, 2019–2025

Across 28 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$81
  • Boehringer Ingelheim$74
  • AstraZeneca$63
  • GSK$46
  • Amarin Pharma, Inc.$42
  • Johnson & Johnson$38
  • plus $125 from 7 others

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$470 in reported general payments places this provider in the 50th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$409,673
Medicare patients
947
Services billed
4,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$217,743
OzempicSemaglutide86$110,825
MounjaroTirzepatide70$74,440
JardianceEmpagliflozin60$67,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$44,093
XareltoRivaroxaban24$38,212
JanuviaSitagliptin Phosphate19$30,311
Breo ElliptaFluticasone/Vilanterol34$25,033
TrulicityDulaglutide12$21,094
MultaqDronedarone Hcl12$20,547
JanumetSitagliptin Phos/Metformin Hcl19$14,791
CreonLipase/Protease/Amylase15$14,474
Rosuvastatin Calcium704$8,014
LivaloPitavastatin Calcium19$7,983
SynthroidLevothyroxine Sodium99$7,441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$81$110,82586 claims
Lilly USA, LLCMounjaro, Trulicity$23$95,53482 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$46$71,93993 claims
Boehringer IngelheimJardiance$74$67,84860 claims
MerckJanuvia, Janumet$26$45,10238 claims
Johnson & JohnsonXarelto$38$38,21224 claims
AbbVieCreon, Synthroid$14$21,915114 claims
Sanofi-aventis U.S. LLCMultaq$15$20,54712 claims
AstraZenecaSymbicort$63$5,92025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →